Engineered Antibodies Provide Extended Relief From Nerve Pain While Preserving Protective Sensation

Researchers developed humanized antibodies targeting Nav1.7, a sodium channel in sensory neurons, to treat neuropathic pain caused by nerve damage. In rat models, these antibodies suppressed abnormal pain signals for up to 96 hours while maintaining the body's normal protective pain responses, outperforming standard medications like pregabalin. This selective approach could offer a new therapeutic avenue for patients suffering from chronic nerve pain that resists conventional treatments.

Neuropathic pain represents a significant clinical challenge because it stems from nerve dysfunction rather than active tissue injury, making conventional pain medications often ineffective. The underlying problem involves sensory neurons misfiring and generating electrical signals that the brain interprets as pain, even in the absence of new damage. Nav1.7 sodium channels play a crucial role in this process by regulating how neurons generate and propagate these pain-related electrical impulses.

The antibody approach offers a mechanistic advantage over existing treatments: by selectively binding to Nav1.7 channels, the engineered proteins can dampen abnormal signaling while leaving normal protective pain responses intact. This selectivity proved important in testing, as the antibodies did not impair motor function or alter pain sensitivity in uninjured animals, suggesting a more targeted intervention than pregabalin, which produced broader neurological effects.